<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="ribavirin/PMC7463888/results/search/drugs/results.xml">
  <result pre="(approved) drugs. A famous example in ophthalmology is represented by" exact="bevacizumab" post="(Avastin®, Roche, Genentech, South San Francisco, CA, USA) for"/>
  <result pre="[10]. The most widely used preservatives in the market are" exact="benzalkonium chloride" post="(BAK; a detergent frequently used in concentration varying from"/>
  <result pre="disinfectants, such as quaternary ammoniums compounds, hexamidine, phenolic compounds, or" exact="chlorhexidine" post="[17]. With regards to the formulations available for ophthalmological"/>
  <result pre="the most common and potentially interesting are those based on" exact="povidone" post="iodine and sodium hypochlorite. Of note, some authors demonstrated"/>
  <result pre="in suspension tests and for contact times of 5 min," exact="povidone" post="iodine (&amp;gt;0.75% free iodine) can inactivate SARS-CoV-2 infectivity in"/>
  <result pre="number of patients. On the other hand, topical application of" exact="chloroquine" post="may also have a repurposing potential. Chloroquine is an"/>
  <result pre="(e.g., retroviruses, flaviviruses, and coronaviruses), including SARS-CoV-2. In eye drops," exact="chloroquine" post="has been recently used at a concentration of 0.03%"/>
  <result pre="to affect the clinical course of viral infections. For example," exact="latanoprost" post="has been associated with herpes virus keratitis, potentially increasing"/>
  <result pre="[53,54]. Similar behavior has been observed with tafluprost, bimatoprost, and" exact="travoprost" post="[55,56,57]. Conversely, timolol maleate acts as an antiviral agent"/>
  <result pre="has been observed with tafluprost, bimatoprost, and travoprost [55,56,57]. Conversely," exact="timolol" post="maleate acts as an antiviral agent and it is"/>
  <result pre="viral infections, such as herpes simplex infections [58]. Of interest," exact="dorzolamide" post="showed antiviral action against oseltamivir-resistant influenza by an in"/>
  <result pre="aminoglycosides (e.g., on Japanese encephalitis and influenza A virus infection)," exact="chloramphenicol" post="(e.g., on human Herpesviridae family), Colistin (polymyxin E, for"/>
  <result pre="family), Colistin (polymyxin E, for example on mycobacteriophage D29 infection),and" exact="fusidic acid" post="(e.g., on human immunodeficiency virus and John Cunningham virus"/>
  <result pre="and Cuevavirus), and Influenza A virus infection [78,79,80]. Of note," exact="ketotifen" post="fumarate has proven to attenuate dengue virus infection [81]."/>
  <result pre="and respiratory syncytial virus (RSV). Some topical immunomodulators, such as" exact="cyclosporine" post="(also used in dry eye therapy), have also shown"/>
  <result pre="effect of interferon (IFN) on replication HSV. In this sense," exact="indometacin" post="and bromfenac has proven to inhibit HSV-1 replication as"/>
  <result pre="interferon (IFN) on replication HSV. In this sense, indometacin and" exact="bromfenac" post="has proven to inhibit HSV-1 replication as they depress"/>
  <result pre="of PrestoBlue® and plating method to evaluate antimicrobial activity of" exact="ascorbic acid," post="boric acid and curcumin in an in vitro gastrointestinal"/>
  <result pre="in vitroInt. J. Mol. Med.19982254154510.3892/ijmm_00000053 47.BrinkevichS.D.BorekoE.SavinovaO.V.PavlovaN.I.ShadyroO.I.Radical-regulating and antiviral properties of" exact="ascorbic acid" post="and its derivativesBioorg. Med. Chem. Lett.2012222424242710.1016/j.bmcl.2012.02.02222390834 48.HoviT.HirvimiesA.StenvikM.VuolaE.PippuriR.Topical treatment of"/>
  <result pre="Ophthalmol. Soc.201354195010.3341/jkos.2013.54.12.1950 56.KrollD.M.SchumanJ.S.Reactivation of herpes simplex virus keratitis after initiating" exact="bimatoprost" post="treatment for glaucomaAm. J. Ophthalmol.200213340140310.1016/S0002-9394(01)01360-511860979 57.YangH.S.ParkH.G.ChoiS.Reactivation of Herpetic Keratitis"/>
  <result pre="Broadly Effective Influenza A AntiviralsPLoS ONE20105e1316910.1371/journal.pone.001316920957181 61.JuurlinkD.N.Safety considerations with chloroquine," exact="hydroxychloroquine" post="and azithromycin in the management of SARS-CoV-2 infectionCan. Med."/>
  <result pre="Influenza A AntiviralsPLoS ONE20105e1316910.1371/journal.pone.001316920957181 61.JuurlinkD.N.Safety considerations with chloroquine, hydroxychloroquine and" exact="azithromycin" post="in the management of SARS-CoV-2 infectionCan. Med. Assoc. J.2020192E450E45310.1503/cmaj.20052832269021"/>
  <result pre="influenza a virus RNA promoterMol. BioSyst.201282857285910.1039/c2mb25333j22990985 66.TopnoR.KhanS.A.ChowdhuryP.MahantaJ.Pharmacodynamics of aminoglycosides and" exact="tetracycline" post="derivatives against Japanese encephalitis virusAsian Pac. J. Trop. Med.2016924124610.1016/j.apjtm.2016.01.03326972394"/>
  <result pre="69.ChanJ.F.-W.MaM.K.-M.ChanG.S.-W.ChanG.C.-W.ChoiG.K.-Y.ChanK.-H.ChengV.C.-C.ChoyB.-Y.YuenK.-Y.ChanK.-W.Rapid reduction of viruria and stabilization of allograft function by" exact="fusidic acid" post="in a renal transplant recipient with JC virus-associated nephropathyInfection20154357758110.1007/s15010-015-0721-x25944568"/>
  <result pre="Acid in HIV InfectionAnn. N. Y. Acad. Sci.199368534134310.1111/j.1749-6632.1993.tb35885.x7689807 71.RhodenE.NixW.A.WeldonW.C.SelvaranganR.Antifungal azoles" exact="itraconazole" post="and posaconazole exhibit potent in vitro antiviral activity against"/>
  <result pre="HIV InfectionAnn. N. Y. Acad. Sci.199368534134310.1111/j.1749-6632.1993.tb35885.x7689807 71.RhodenE.NixW.A.WeldonW.C.SelvaranganR.Antifungal azoles itraconazole and" exact="posaconazole" post="exhibit potent in vitro antiviral activity against clinical isolates"/>
  <result pre="B Methyl EsterAntimicrob. Agents Chemother.19781319920410.1128/AAC.13.2.199206201 73.SchloerS.GoretzkoJ.KühnlA.BrunotteL.LudwigS.RescherU.The clinically licensed antifungal drug" exact="itraconazole" post="inhibits influenza virus in vitro and in vivoEmerg. Microbes"/>
  <result pre="the Treatment of Ocular DiseasesBioDrugs2011258910310.2165/11587010-000000000-0000021443273 78.HeS.LinB.ChuV.HuZ.HuX.XiaoJ.WangA.Q.SchweitzerC.J.LiQ.ImamuraM.et al.Repurposing of the antihistamine" exact="chlorcyclizine" post="and related compounds for treatment of hepatitis C virus"/>
  <result pre="of antiviral therapy for hepatitis C after liver transplantation with" exact="cyclosporine" post="and tacrolimus: A systematic review and meta-analysisLiver Transplant.201219364810.1002/lt.23516 86.QingM.YangF.ZhangB.ZouG.RobidaJ.M.YuanZ.TangH.ShiP.-Y.Cyclosporine"/>
  <result pre="Host Cyclophilins and Viral NS5 ProteinAntimicrob. Agents Chemother.2009533226323510.1128/AAC.00189-0919451286 87.MaC.LiF.MusharrafiehR.G.WangJ.Discovery of" exact="cyclosporine" post="A and its analogs as broad-spectrum anti-influenza drugs with"/>
  <result pre="Binding of Two Different CoronavirusesJ. Virol.2011855331533710.1128/JVI.02274-1021411533 107.ItoM.BabaM.SatoA.PauwelsR.De ClercqE.ShigetaS.Inhibitory effect of" exact="dextran" post="sulfate and heparin on the replication of human immunodeficiency"/>
 </snippets>
</snippetsTree>
